Please use this identifier to cite or link to this item:
Authors: Frei, Katahrina
Schechter, Sabrina
Daher, Tamas
Hörner, Nina
Richter, Jutta
Hildebrand, Ute
Schindeldecker, Mario
Witzel, Hagen R.
Tsaur, Igor
Porubsky, Stefan
Gaida, Matthias M.
Roth, Wilfried
Tagscherer, Karin E.
Title: Inhibition of the Cyclin K-CDK12 complex induces DNA damage and increases the effect of androgen deprivation therapy in prostate cancer
Online publication date: 18-Jan-2024
Year of first publication: 2023
Language: english
Abstract: Androgen deprivation therapy (ADT) is the mainstay of the current first-line treatment concepts for patients with advanced prostate carcinoma (PCa). However, due to treatment failure and recurrence investigation of new targeted therapeutics is urgently needed. In this study, we investigated the suitability of the Cyclin K-CDK12 complex as a novel therapeutic approach in PCa using the new covalent CDK12/13 inhibitor THZ531. Here we show that THZ531 impairs cellular proliferation, induces apoptosis, and decreases the expression of selected DNA repair genes in PCa cell lines, which is associated with an increasing extent of DNA damage. Furthermore, combination of THZ531 and ADT leads to an increase in these anti-tumoral effects in androgen-sensitive PCa cells. The anti-proliferative and pro-apoptotic activity of THZ531 in combination with ADT was validated in an ex vivo PCa tissue culture model. In a retrospective immunohistochemical analysis of 300 clinical tissue samples we show that Cyclin K (CycK) but not CDK12 expression correlates with a more aggressive type of PCa. In conclusion, this study demonstrates the clinical relevance of the CycK-CDK12 complex as a promising target for combinational therapy with ADT in PCa and its importance as a prognostic biomarker for patients with PCa.
DDC: 610 Medizin
610 Medical sciences
Institution: Johannes Gutenberg-Universität Mainz
Department: FB 04 Medizin
Place: Mainz
Version: Published version
Publication type: Zeitschriftenaufsatz
License: CC BY
Information on rights of use:
Journal: International journal of cancer
Version of Record (VoR)
Publisher: Wiley-Liss
Publisher place: Bognor Regis
Issue date: 2023
ISSN: 0020-7136
Publisher DOI: 10.1002/ijc.34778
Appears in collections:DFG-491381577-H

Files in This Item:
  File Description SizeFormat
inhibition_of_the_cyclin_kcdk-20240118090836421.pdf30.97 MBAdobe PDFView/Open